×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Company: AD Neuroimmune Checkpoint and TREM2 Pathway Companies
company
1,640 words
KG: Ad
Contents
AD Neuroimmune Checkpoint and TREM2 Pathway Companies
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (24)
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
Mitochondrial RNA Granule Rescue Pathway
Score: 0.66
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
← Prev
pg 2/2
Related Analyses (21)
What are the optimal timing windows for TREM2 agonism vs ant
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Does SYK activation provide neuroprotection or exacerbate ne
neurodegeneration · archived
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · completed
Neuroinflammation and microglial priming in early AD
neurodegeneration · completed
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Show 16 more
Related Experiments (4)
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
See Also (15)
Down Syndrome Neurodegeneration Pathway
mechanism · Pages share 6 hypotheses
HMGB1 Signaling in Neurodegeneration
mechanism · Pages share 6 hypotheses
Antibody Therapy in Neurodegeneration
mechanism · Pages share 6 hypotheses
COVID-19 Neurodegeneration Mechanism
mechanism · Pages share 6 hypotheses
Endosomal-Lysosomal Pathway in Neurodegeneration
mechanism · Pages share 6 hypotheses
gp130/IL-6 Family Cytokine Signaling in Neurodegenerati
mechanism · Pages share 6 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 6 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 6 hypotheses
Axon Guidance Pathways in Neurodegeneration
mechanism · Pages share 6 hypotheses
Convergent Pathways in Neurodegeneration
mechanism · Pages share 6 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 6 hypotheses
Dystrophic Neurites in Neurodegeneration
mechanism · Pages share 6 hypotheses
Galectin-3 Mechanism in Neurodegeneration
mechanism · Pages share 6 hypotheses
Geniposide for Alzheimer's disease - immune biomarker t
mechanism · Pages share 6 hypotheses
IL-1 Signaling Pathway in Neurodegeneration
mechanism · Pages share 6 hypotheses
Show 10 more
Knowledge Graph (11 edges)
TDP-43
associated_with
Ad
32126838
cannot be concluded ineffective for
Ad
30541566
were significantly higher in
Ad
30541566
was reduced in early stages and highly increased in
Ad
30541566
were increased in
Ad
30541566
was highly increased in
Ad
41660275
significantly elevated in
Ad
41660275
positively correlated in CN but attenuated in
Ad
41660275
elevated in
Ad
39000217
is among the processes affected by
Ad
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)